BioSpace News Archive

Cyclo Therapeutics, Inc. today reported its financial results for the second quarter of 2021, and provided a business update.

Nxt-ID, Inc. (NASDAQ: NXTD) (the “Company” or “Nxt-ID”), a provider of technology products and services for healthcare applications, announces financial results for the three months and six months ended June 30, 2021.

Napo Pharmaceuticals, Inc. announced today the completion of an additional preclinical toxicology study intended to support continued development of NP-300 (lechlemer) for the symptomatic relief of diarrhea from cholera and other infectious diarrheal conditions.

Bearpac Medical, LLC has been selected to exhibit the Passio Pump Drainage System for the drainage of recurrent and symptomatic pleural effusions at the Vizient Innovative Technology Exchange.

Emmaus Life Sciences, Inc. announced today that on August 12, 2021 , the National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain approved a Temporary License for Importation of Pharmaceutical Product for Endari.®

AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has received a written pre-investigational new drug (pre-IND) response from the U.S. Food and Drug Administration (FDA) for MMS019, its patented and proprietary high-density molecular masking spray under development for use as an anti-viral barrier product.

Cosmos Holdings, Inc., international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, provided a business update and reported financial results for the second quarter ended June 30, 2021.

Tempus, a leader in artificial intelligence and precision medicine, today announced the submission of a Premarket Approval (PMA) application for its proprietary broad-panel DNA sequencing assay to the U.S. Food and Drug Administration (FDA).

Avadim Health, Inc., a healthcare and wellness provider, today announced it has completed the court-approved sale of substantially all its assets to a newly-created company owned by funds managed by Hayfin Capital Management (Hayfin) following a Chapter 11 process.